Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease.
作者信息
Kazi Sajida, Mathur Abhinav, Wilkie Gwen, Cheal Kirsty, Battle Richard, McGowan Neil, Fraser Neil, Hargreaves Emily, Turner David, Campbell John D M, Turner Marc, Vickers Mark A
机构信息
Department of Haematology, Aberdeen Royal Infirmary.
University of Aberdeen.
出版信息
Haematologica. 2019 Aug;104(8):e356-e359. doi: 10.3324/haematol.2018.207548. Epub 2019 Feb 21.
Abstract
摘要
相似文献
1
Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease.第三方病毒特异性细胞毒性淋巴细胞治疗免疫抑制和爱泼斯坦-巴尔病毒相关淋巴增殖性疾病后的长期随访
Haematologica. 2019 Aug;104(8):e356-e359. doi: 10.3324/haematol.2018.207548. Epub 2019 Feb 21.
2
Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.造血干细胞移植后 EBV 相关移植后淋巴增殖性疾病（PTLD）。
Eur J Haematol. 2018 Sep;101(3):283-290. doi: 10.1111/ejh.13131. Epub 2018 Aug 3.
3
T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.慢性活动性EB病毒感染中的T细胞库及EB病毒特异性T细胞反应：一项病例研究
Clin Immunol. 2006 Apr;119(1):79-86. doi: 10.1016/j.clim.2005.11.008. Epub 2006 Jan 4.
4
Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.针对异基因骨髓移植后并发的爱泼斯坦-巴尔病毒相关淋巴增殖性疾病的过继性免疫治疗。
Springer Semin Immunopathol. 1998;20(3-4):455-91. doi: 10.1007/BF00838055.
5
Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.用于移植后淋巴细胞增生性疾病过继性免疫治疗的爱泼斯坦-巴尔病毒特异性细胞毒性T淋巴细胞
Blood Rev. 2004 Sep;18(3):193-209. doi: 10.1016/j.blre.2003.12.002.
6
Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.移植后淋巴细胞增生性疾病及其他与爱泼斯坦-巴尔病毒相关的恶性肿瘤的治疗选择。
Tissue Antigens. 2004 Apr;63(4):285-92. doi: 10.1111/j.0001-2815.2004.00227.x.
7
[Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes in EBV-related diseases].[爱泼斯坦-巴尔病毒（EBV）相关疾病中EBV特异性CD8 + T淋巴细胞的定量分析]
Rinsho Ketsueki. 2000 Jun;41(6):487-90.
8
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.采用部分人类白细胞抗原匹配的异基因细胞毒性T细胞治疗爱泼斯坦-巴尔病毒阳性移植后淋巴细胞增生性疾病。
Lancet. 2002 Aug 10;360(9331):436-42. doi: 10.1016/S0140-6736(02)09672-1.
9
EBV specific CTL: a model for immune therapy.EBV特异性细胞毒性T淋巴细胞：一种免疫治疗模型。
Vox Sang. 1998;74 Suppl 2:497-8. doi: 10.1111/j.1423-0410.1998.tb05463.x.
10
Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.确定EB病毒感染在移植后淋巴增生性疾病发展过程中的病毒学、血清学和免疫学参数。
Int Immunol. 2004 Jul;16(7):983-9. doi: 10.1093/intimm/dxh099. Epub 2004 May 24.
引用本文的文献
1
Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy.用于现成过继性细胞疗法的低同种异体免疫原性多特异性嵌合抗原受体T细胞和严重急性呼吸综合征冠状病毒2特异性T细胞的优化
Mol Ther Methods Clin Dev. 2025 Apr 10;33(2):101462. doi: 10.1016/j.omtm.2025.101462. eCollection 2025 Jun 12.
2
Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.用于免疫功能低下患者病毒感染管理的病毒特异性T细胞疗法
Transfus Med Hemother. 2024 Sep 25;52(1):5-26. doi: 10.1159/000540961. eCollection 2025 Feb.
3
Clinical imaging and pathology analysis of Epstein-Barr virus-associated monomorphic lymphoproliferative disease after liver transplantation in children-a retrospective case series.儿童肝移植后爱泼斯坦-巴尔病毒相关单形性淋巴增殖性疾病的临床影像学与病理分析——一项回顾性病例系列研究
Transl Pediatr. 2024 Dec 31;13(12):2282-2291. doi: 10.21037/tp-24-311. Epub 2024 Dec 27.
4
Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo.干细胞记忆 EBV 特异性 T 细胞控制 EBV 肿瘤生长并在体内持续存在。
Sci Adv. 2024 Aug 23;10(34):eado2048. doi: 10.1126/sciadv.ado2048.
5
Applications of cell therapy in the treatment of virus-associated cancers.细胞治疗在病毒相关性癌症治疗中的应用。
Nat Rev Clin Oncol. 2024 Oct;21(10):709-724. doi: 10.1038/s41571-024-00930-x. Epub 2024 Aug 19.
6
EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation.经肽选择生成的 EBV T 细胞免疫疗法与 LCL 刺激相比，具有增强的效应功能。
Front Immunol. 2024 Jul 1;15:1412211. doi: 10.3389/fimmu.2024.1412211. eCollection 2024.
7
Post-transplantation Lymphoproliferative Disorder (PTLD): In the Liver Transplant Recipient.移植后淋巴细胞增生性疾病（PTLD）：肝移植受者中的情况
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101286. doi: 10.1016/j.jceh.2023.09.007. Epub 2023 Sep 20.
8
EBV-induced T-cell responses in EBV-specific and nonspecific cancers.EBV 诱导的 T 细胞反应在 EBV 特异性和非特异性癌症中的作用。
Front Immunol. 2023 Sep 29;14:1250946. doi: 10.3389/fimmu.2023.1250946. eCollection 2023.
9
How I treat posttransplant lymphoproliferative disorder.我如何治疗移植后淋巴组织增生性疾病。
Blood. 2023 Oct 26;142(17):1426-1437. doi: 10.1182/blood.2023020075.
10
Trans-population graph-based coverage optimization of allogeneic cellular therapy.基于跨群体图的同种异体细胞治疗覆盖优化。
Front Immunol. 2023 May 5;14:1069749. doi: 10.3389/fimmu.2023.1069749. eCollection 2023.
本文引用的文献
1
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.利妥昔单抗诱导反应是 B 细胞移植后淋巴组织增生性疾病的预测标志物，并允许在一项国际性、前瞻性、多中心 II 期试验中成功分层为利妥昔单抗或 R-CHOP 巩固治疗。
J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19.
2
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.基于利妥昔单抗的治疗，随后进行过继性细胞免疫治疗，用于经活检证实的异基因造血干细胞移植受者的EB病毒相关移植后淋巴增殖性疾病。
Oncoimmunology. 2016 Mar 10;5(5):e1139274. doi: 10.1080/2162402X.2016.1139274. eCollection 2016 May.
3
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.异基因造血干细胞移植后患者的爱泼斯坦-巴尔病毒感染及移植后淋巴增殖性疾病的管理：第六届欧洲白血病感染会议（ECIL-6）指南
Haematologica. 2016 Jul;101(7):803-11. doi: 10.3324/haematol.2016.144428.
4
Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.在抢先使用利妥昔单抗时代，高危异基因造血干细胞移植后爱泼斯坦-巴尔病毒相关并发症的影响
Bone Marrow Transplant. 2015 Apr;50(4):579-84. doi: 10.1038/bmt.2014.298. Epub 2015 Jan 12.
5
Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.建立并运营一个符合药品生产质量管理规范的同种异体爱泼斯坦-巴尔病毒（EBV）特异性细胞毒性细胞库，用于治疗EBV相关淋巴增殖性疾病。
Br J Haematol. 2014 Nov;167(3):402-10. doi: 10.1111/bjh.13051. Epub 2014 Jul 26.
6
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后与 EBV 相关的移植后淋巴增殖性疾病的危险因素。
Haematologica. 2014 Feb;99(2):346-52. doi: 10.3324/haematol.2013.087338. Epub 2013 Sep 20.
7
T-cell therapy in the treatment of post-transplant lymphoproliferative disease.T 细胞疗法治疗移植后淋巴组织增生性疾病。
Nat Rev Clin Oncol. 2012 Sep;9(9):510-9. doi: 10.1038/nrclinonc.2012.111. Epub 2012 Jul 17.
8
Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease.患有爱泼斯坦-巴尔病毒血症和移植后淋巴细胞增生性疾病的小儿肝移植患者的移植物排斥反应。
Pediatr Transplant. 2012 Aug;16(5):458-64. doi: 10.1111/j.1399-3046.2012.01713.x. Epub 2012 May 4.
9
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.利妥昔单抗序贯 CHOP 化疗治疗成人 B 细胞移植后淋巴组织增生性疾病（PTLD）：前瞻性国际多中心 2 期 PTLD-1 试验。
Lancet Oncol. 2012 Feb;13(2):196-206. doi: 10.1016/S1470-2045(11)70300-X. Epub 2011 Dec 13.
10
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后，采用未经选择或 EBV 特异性 T 细胞进行活检证实的 EBV+淋巴瘤的过继免疫治疗。
Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.
Zotero 插件